Corporate support helps the GI Cancer Institute unlock the answers to better treatments for the 24,600 Australians diagnosed with gastro-intestinal (GI) cancer each year.
With 33 Australians losing their battle to the disease every day, the stakes are high.
The GI Cancer Institute aims to raise money for GI cancer clinical trials research conducted by the Australasian Gastro-Intestinal Trials Group (AGITG). The AGITG is comprised of over 850 medical professionals who volunteer their time. AGITG research is conducted independently of the corporate supporters of the GI Cancer Institute.
The GI Cancer Institute thanks the following companies for their recent support.
STA is a bio-pharmaceutical company dedicated to working with leading international pharmaceutical and diagnostic companies to provide patient access to innovative healthcare solutions.
With the highest professional and ethical standards we commercialise therapies and technologies that uniquely fulfil the unmet medical needs of our community.
The STA therapeutic portfolio and pipeline at present encompasses oncology, haematology, urology and ophthalmology.
In November 2014, ABRAXANE ® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine was listed on the Pharmaceutical Benefits Scheme for eligible patients with metastatic pancreatic cancer.
Additional information can be found at www.specialisedtherapeutics.com.au
At Shire, we enable people with life-altering conditions to lead better lives. We focus on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Gaucher disease or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
We are also given great support by many media in the form of airplay of our community service announcements
and other unpaid promotions. These currently include: